Treatment of urticarial vasculitis: A systematic review

Kolkhir P. V., Grakhova M., Bonnekoh H., Krause K., Maurer M.

Journal of Allergy and Clinical Immunology

Vol.143, Issue2, P. 458-466

Опубликовано: 2019

Тип ресурса: Статья

DOI:10.1016/j.jaci.2018.09.007

Аннотация:

Urticarial vasculitis (UV) is a difficult-to-treat condition characterized by long-lasting urticarial rashes and histopathologic findings of leukocytoclastic vasculitis. Treatment is dictated by the severity of skin and systemic involvement and the underlying systemic disease. This is a comprehensive systematic review of the efficacy of current UV treatment options. We searched for relevant studies in 7 databases, including MEDLINE, Scopus, and Web of Science. In total, 261 eligible studies and 789 unique patients with UV were included in the systematic review. Most patients with UV are adult women with chronic (≥6 weeks) and systemic disease. UV is mostly idiopathic but can be associated with drugs, malignancy, autoimmunity, and infections. It usually resolves with their withdrawal or cure. Corticosteroids are effective for the treatment of skin symptoms in more than 80[%] of patients with UV. However, their long-term administration can lead to potentially serious adverse effects. The a

Ключевые слова:

review; treatment; Urticarial vasculitis

anakinra; azathioprine; biological product; canakinumab; colchicine; corticosteroid; cyclophosphamide; cyclosporine; danazol; dapsone; doxepin; histamine H1 receptor antagonist; histamine H2 receptor antagonist; hydroxychloroquine; immunoglobulin; immunosuppressive agent; infliximab; montelukast; mycophenolate mofetil; nonsteroid antiinflammatory agent; omalizumab; pentoxifylline; rituximab; tocilizumab; tranexamic acid; allergic asthma; Article; autoimmunity; biological therapy; Biosis; corticosteroid therapy; drug safety; human; immunosuppressive treatment; infection; leukocytoclastic vasculitis; long term care; Medline; monotherapy; plasmapheresis; priority journal; prospective study; rash; retrospective study; Scopus; skin manifestation; systematic review; systemic disease; ultraviolet phototherapy; ultraviolet radiation; urticaria; urticarial vasculitis; vasculitis; Web of Science

Язык текста: Английский

ISSN: 1097-6825

Kolkhir P. V. Pavel Vladimirovich 1982-

Grakhova M.

Bonnekoh H.

Krause K.

Maurer M.

Колхир П. В. Павел Владимирович 1982-

Грахова М.

Боннекох Х.

Краусе К.

Маурер М.

Treatment of urticarial vasculitis: A systematic review

Текст визуальный непосредственный

Journal of Allergy and Clinical Immunology

Mosby

Vol.143, Issue2 P. 458-466

2019

Статья

review treatment Urticarial vasculitis

anakinra azathioprine biological product canakinumab colchicine corticosteroid cyclophosphamide cyclosporine danazol dapsone doxepin histamine H1 receptor antagonist histamine H2 receptor antagonist hydroxychloroquine immunoglobulin immunosuppressive agent infliximab montelukast mycophenolate mofetil nonsteroid antiinflammatory agent omalizumab pentoxifylline rituximab tocilizumab tranexamic acid allergic asthma Article autoimmunity biological therapy Biosis corticosteroid therapy drug safety human immunosuppressive treatment infection leukocytoclastic vasculitis long term care Medline monotherapy plasmapheresis priority journal prospective study rash retrospective study Scopus skin manifestation systematic review systemic disease ultraviolet phototherapy ultraviolet radiation urticaria urticarial vasculitis vasculitis Web of Science

Urticarial vasculitis (UV) is a difficult-to-treat condition characterized by long-lasting urticarial rashes and histopathologic findings of leukocytoclastic vasculitis. Treatment is dictated by the severity of skin and systemic involvement and the underlying systemic disease. This is a comprehensive systematic review of the efficacy of current UV treatment options. We searched for relevant studies in 7 databases, including MEDLINE, Scopus, and Web of Science. In total, 261 eligible studies and 789 unique patients with UV were included in the systematic review. Most patients with UV are adult women with chronic (≥6 weeks) and systemic disease. UV is mostly idiopathic but can be associated with drugs, malignancy, autoimmunity, and infections. It usually resolves with their withdrawal or cure. Corticosteroids are effective for the treatment of skin symptoms in more than 80[%] of patients with UV. However, their long-term administration can lead to potentially serious adverse effects. The a